Effects of Rapamycin Combined with Cisplatin on Tumor Necrosis Factor TNF-\(\alpha\) in MG-63 Cells

Tian-Yu Han\(^1\)*, Bin Ma\(^2\)*, Bing Hu\(^3\), Liang-Bi Xiang\(^1\), and Xin-Wei Liu\(^1\)®

Abstract
Rapamycin (RAPA) and cisplatin (CDDP) are used as clinical drugs in the treatment of various tumors, but there are few studies on the combination of RAPA and CDDP. Tumor necrosis factor \(\alpha\) (TNF-\(\alpha\)) plays an important role in tumorigenesis and development. This study is to explore the effects of RAPA combined with CDDP on the expression of TNF-\(\alpha\) in osteosarcoma MG-63 cells. MG-63 cells were routinely cultured and divided into a control group, a RAPA group (20 \(\mu\)M), a CDDP group (20 \(\mu\)M), and a RAPA + CDDP group (20 \(\mu\)M + 20 \(\mu\)M). The four groups were treated with drugs for 24 and 48 h, respectively. Real-time polymerase chain reaction (PCR), Western blot (WB), and immunocytochemistry (ICC) were adopted to detect the expression of TNF-\(\alpha\) gene and protein. The results of PCR showed that both the separate drug use and drug combination could significantly lower the relative expression quantity of TNF-\(\alpha\) gene (*\(P < 0.5\)), but the combination was more effective (*\(P < 0.5\)); the expression quantity of TNF-\(\alpha\) gene in the RAPA + CDDP group at 48 h was much lower than that at 24 h (**\(P < 0.01\)). The results of WB showed that both the separate drug use and drug combination could significantly lower the relative expression quantity of TNF-\(\alpha\) protein, and the combination was more effective than separate drug use (*\(P < 0.05\) and more effective at 48 h (**\(P < 0.01\)); the expression quantity of TNF-\(\alpha\) protein in the same group at 48 h was much lower than that at 24 h (*\(P < 0.05\)). The results of ICC showed that both the separate drug use and drug combination could significantly lower the relative expression quantity of TNF-\(\alpha\) protein, and the combination was more effective than separate drug use (**\(P < 0.01\) and more effective at 48 h (**\(P < 0.001\)); the expression quantity of TNF-\(\alpha\) protein in the same group at 48 h was much lower than that at 24 h (**\(P < 0.01\)). RAPA combined with CDDP can significantly reduce the expression of TNF-\(\alpha\) in MG-63 cells, which is time dependent.

Keywords
RAPA, CDDP, MG-63, TNF-\(\alpha\)

Introduction
Osteosarcoma is a primary bone tumor with a high degree of malignancy in adolescents. Its incidence accounts for about 3% of adolescent malignant tumors. Osteosarcoma is mainly characterized by fast growth, strong invasion ability, high metastasis rate, and so on.\(^1,2\) Although operation, chemotherapy, and other treatment means have been more and more effective in recent years, patients’ prognosis is still poor and is complicated with high fatality rate and disability rate.\(^3,4\) It is reported that the 5-year survival rate of patients with localized osteosarcoma is about 60% to 70% and that of patients with metastatic osteosarcoma only 20%. Moreover, about 80% of patients often clinically have lung or other metastases when they are diagnosed with osteosarcoma.\(^5\) Therefore, it is necessary to further learn about the molecular mechanism of its tumorigenesis and development on the

\(^{1}\) Department of Orthopaedics, General Hospital of Northern Theater Command, Shenyang, Liaoning, China
\(^{2}\) Division of Spine Surgery, Department of Orthopaedics, Tongji Hospital, Tongji University School of Medicine, Shanghai, China
\(^{3}\) Department of Medical Oncology, Shanghai Minhang TCM Hospital (Shanghai Minhang Hospital of Traditional Chinese Medicine), China
\(^*\) Both the authors contributed equally to this article

Submitted: March 14, 2020. Revised: April 10, 2020. Accepted: April 20, 2020.

Corresponding Author:
Xin-Wei Liu, Department of Orthopaedics, General Hospital of Northern Theater Command, Shenyang, Liaoning 110016, China.
Email: blivfd@sina.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
basis of original therapy, so as to find effective treatment strategies. Key factors regulating invasion and metastasis of osteosarcoma were identified at the gene level, and the process was clarified to provide the corresponding theoretical basis and make contributions to the early cure of osteosarcoma. In 1975, Carswell et al. found a special protein in the serum of mice infected by BCG injection or bacterial endotoxin. Therefore, this substance was named tumor necrosis factor (TNF). TNF is a glycoprotein and exists in the form of TNF-α or TNF-β. Afterwards, with the deepening of research, researchers found that TNF has more and more prominent antitumor effects. In particular, TNF-α has significant effects. TNF-α induces apoptosis of tumor cells by combining with the TNF receptor (TNFR). On the cytomembrane. It can also promote the proliferation and differentiation of immune cells and impose antitumor effects. In addition to antitumor effect, as one of the important inflammatory factors, TNF-α also plays an important role in the pathogenesis of insulin resistance and type 2 diabetes. Its abnormal expression in patients with nasal polypl also has a certain effect. In terms of its high expression in patients with thyroiditis, its promoting effect on the apoptosis of thyroid cells has been verified by in vivo experiments. In recent years, the therapies for malignant tumors are excision and chemoradiotherapy. The use of antitumor drugs is beneficial to postoperative recovery of patients. More and more antitumor drugs have been clinically used. However, the frequent use of chemotherapy drugs leads to the increased drug resistance in patients, thus the effect is not ideal. Rapamycin (RAPA) and cisplatin (CDDP) are ideal chemotherapy drugs clinically used for tumor treatment. They are significantly effective on ovarian cancer, lung cancer, liver cancer, endometrial cancer, prostate cancer, and other tumors. In this study, osteosarcoma MG-63 cells were divided into four groups, i.e., a control group, a RAPA group, a CDDP group, and a RAPA + CDDP group to detect the expression quantity of TNF. The results of statistical analysis clarified the killing effect of the combination of the two drugs on tumor cells.

Materials and Methods

Cell Culture

Human osteosarcoma MG-63 cells were purchased from Shanghai Cell Bank (Shanghai, China), Chinese Academy of Sciences. Dulbecco’s Modified Eagle Medium (DMEM) culture medium was used; 10% fetal calf serum (FBS), 1% nonessential amino acid, and 2 mmol/l glutamine were added. The cells were routinely cultured at 37°C and in an environment with 5% CO₂. The cell state was adjusted. Cells in logarithmic phase were selected. MG-63 cells were randomly divided into four groups and intervened with 20 μM CDDP, 20 μM RAPA (R8140; Solarbio, Beijing, China), and 20 μM CDDP + 20 μM RAPA, respectively. The normal control group was intervened with drug solvents. The cells in the four groups were collected 24 and 48 h later for subsequent experiments. CDDP was purchased from Qilu Pharmaceutical Co., Ltd (Jinan, Shandong, China). The batch number was H37021362.

Real-Time Polymerase Chain Reaction

The treated cells were collected by groups. TRIPure extraction kit (RP1001; BioTek, Beijing, China) was used as instructed to extract the total RNA in each group. The instrument NanoDrop-2000 (Thermo Fisher Scientific, MA, USA) was used to determine the RNA concentration in each group. Real-time polymerase chain reaction (PCR) (Exicycler 96, BIONEER, Daejeon, Republic of Korea) was used, and super M-MLV reverse transcriptase (PR6502; BioTek) was used for reverse transcription. Power Taq PCR MasterMix (PR1702; BioTek) and SYBR Green I (SY1020; Solarbio) were used for PCR. β-actin was used as a reference. The formula was used to calculate the relative expression quantity of mRNA of TNF-α gene. See Table 1 for primer sequence. It is synthesized by Sangon Biotech (Shanghai) Co., Ltd. (Shanghai, China).

Western Blot

The treated cells in each group were collected and split with the RIPA lysis buffer (P0100; Solarbio) containing 1 mM phenyl methane on the icebox for 5 min, and then the cells were centrifuged at 12,000 rpm and 4°C for 10 min. The supernatant was separated to obtain protein extract. Bicinchoninic acid (BCA) protein assay kit (PC0020, Solarbio) was used to quantify the total protein extracted. According to the procedures of Western blot (WB), 8% sodium dodecyl sulfate-polyacylamide gel was used for electrophoresis. The protein bands from separation were transferred to the PVDF membrane (IPVH00010; Millipore, MA, USA). The polyvinylidene fluoride (PVDF) membrane was sealed with 5% skim milk, and then TNF-α primary antibody (diluted by 1:1,000; GB13188 -1; Servicebio, Wuhan, China) was added. The PVDF membrane was incubated at 4°C

| Name of primer | Former primer (5’–3’) | Back primer (5’–3’) |
|---------------|-----------------------|--------------------|
| TNF-α         | CGAGTGAACAGCCGTAGCC    | TTGAAGAGGACCTGGGAGTAG |
| β-actin       | CACTGTGCCCATCTACGAGG   | TAATGTCAACGACAGATTTC |

TNF-α: tumor necrosis factor α.
overnight. Upon the completion of incubation, the PVDF membrane was washed with Tris Buffered saline Tween (TBST). The horseradish peroxidase (HRP)-labeled sheep anti-rabbit IgG (diluted by 1:3,000; SE134; Solarbio) was added for incubation. β-actin was incubated by the same procedures. Finally, electrochemiluminescence (ECL) luminous fluid (PE0010; Solarbio) was added for exposure in a darkroom. The film was scanned. The gel image processing system (the software Gel-Pro-Analyzer, Bio-Rad, State of California, USA) was used to analyze the optical density of the target band.

**Immunocytochemistry**

The cells treated in each groups were made into cell slides. Paraformaldehyde solution (4%) was used for fixation for 15 min. The formaldehyde was discarded. Triton X-100 (0.1%) was added for incubation at ambient temperature for 20 min. Phosphate buffer saline (PBS) (0.01 M) was added for immersion for 5 min for three times. PBS was discarded. H₂O₂ (3%) was added for incubation for 15 min, and then 0.01 M PBS was added for immersion for 5 min for three times. PBS was removed. The serum was added for sealing for 15 min. The serum was discarded, and the TNF-α primary antibody diluted with PBS by 1:2,000 (GB13188-2; Servicebio) was added. The mixture was placed at 4°C overnight. The primary antibody was discarded. PBS (0.01 M) was added for immersion for 5 min for three times. PBS was discarded. PBS was used to dilute the HRP-labeled goat anti-rabbit secondary antibody by 100 times (diluted by 1:1,000; G1213; Servicebio). The mixture was added to completely cover the cells. The cells were incubated at 37°C for 1 h. The secondary antibody was removed. PBS (0.01 M) was added for immersion for 5 min for three times. PBS was discarded. DAB was added for developing. Hematoxylin was used for redyeing (G1004-100; Servicebio). Sealing was performed. The dyeing effects were observed and photographed under the microscope. The software Image-Pro Plus was used for optical density analysis.

**Results**

The Results of Real-Time PCR Showed that the Expression Quantity of TNF-α Gene Decreased Significantly After Drug Treatment

PCR results showed that, for the four groups at the same time point, both separate drug use and drug combination can significantly lower the expression quantity of TNF-α gene, drug combination was more effective than separate drug use, and there was significant difference; for the same group at different time points, although separate drug use can decrease the expression of TNF-α gene, the significant difference level could not be reached; the expression quantity after 48 h of drug combination was significantly lower than that after 24 h, and the extremely significant difference level could be reached (Fig. 1).  

**WB Results Showed that the Expression Quantity of TNF-α Protein Decreased Significantly After Drug Use**

Expression quantity of TNF-α protein in each group in WB quantitative analysis is shown in the Fig. 2. The expression in different groups at the same time point showed that both separate drug use and drug combination could significantly lower the expression quantity of TNF-α protein, and an extremely significant difference level could be reached; the expression quantity after 24 h of drug combination was significantly lower than that after separate drug use, and a significant difference level could also be reached; the expression quantity after 48 h of drug combination was significantly lower than that after separate drug use, reaching an extremely significant difference. In terms of the comparison of expression quantity in the same group at different time points, the expression quantity of TNF-α protein after 48 h of
separate drug use and drug combination was significantly lower than that after 48 h of drug use and was time dependent to some extent (Fig. 2A, B).

**Immunocytochemistry Results Showed that the Expression Quantity of TNF-α Protein Decreased Significantly After Treatment with Drug(s)**

The cells in the four groups were made into cell slides for immunocytochemistry dyeing. The results showed that (1) 24 h of separate drug use and drug combination could significantly lower the expression quantity of TNF-α protein and reach an extremely significant difference level; the expression quantity after drug combination was significantly lower than that after separate drug use. Forty-eight hours of separate drug use and drug combination could significantly lower the expression quantity of TNF-α protein and reach an extremely significant difference level; the expression quantity after drug combination was lower than that after separate drug use. (2) The expression quantity after 48 h of drug use was lower than that after 24 h of drug use in the same group, showing significant difference (Fig. 3A, B).

**Discussion**

As one of the most common primary bone cancers in adolescents, osteosarcoma has seriously threatened the lives and health of children and caused a burden on families. In recent years, researchers have paid more and more attention to osteosarcoma and have begun to study osteosarcoma in depth, in order to explore its mechanism, develop different chemotherapy drugs, and identify its pathogenic factors at the molecular level. They hope to primarily cure osteosarcoma, realize early detection, early diagnosis and early treatment, and improve the quality of life and health level of human beings.

As an important member of TNF family, TNF-α has remarkable antitumor effect and a wide range of biological activities and now is the factor with the most powerful antitumor effect. Therefore, it is of vital importance to explore its antitumor mechanism and enhance its antitumor effect. In this study, the expression of TNF-α in different groups by treating osteosarcoma with chemotherapy drugs, so as to prove its changes in the tumorigenesis and development. A great number of studies have shown that except the direct inhibition of proliferation and promotion of necrocytosis of tumor cells, TNF-α is also correlated to other diseases to some extent. The abnormal expression of TNF-α may cause apoptosis of myocardial cells, lead to heart failure and eventually cause death. Besides, TNF-α is involved in several autoimmune diseases, such as rheumatoid arthritis and psoriatic arthritis. Some other studies have shown that it is also associated with asthma, sepsis, chronic obstructive pulmonary disease, and other diseases. As the most active cytokine, TNF-α is also involved in the development of many
CDDP has been widely applied and has developed rapidly since its discovery. It has good antitumor effect and high antitumor activity, and has been used as a preferred drug for cancers, such as breast cancer, melanoma, liver cancer, esophageal cancer, and cervical cancer \(^{29,30}\). Nevertheless, CDDP also has some side effects, mainly including nephrotoxicity, nausea, and vomiting. Its toxicity profiles differ from those of other antitumor drugs. Moreover, it does not have cross tolerance, which is beneficial to clinical drug combination. RAPA was first found to have immunosuppressive effects and might be used to deal with organ transplant rejection. Afterward, it was found to be able to specifically inhibit Mammalian target of rapamycin (MTOR) signal transduction pathway. Proteins associated with this pathway are normally expressed in multiple tumors and affect tumorigenesis by regulating this pathway. Therefore, RAPA can induce the apoptosis of tumor cells and exert its anticancer effect \(^{31}\). The effects of drug combination were proved by comparing the combination of CDDP and RAPA with separate drug use and detecting the expression of TNF-\(\alpha\) and through experimental results. The findings also proved that both of the two drugs can lower the high expression of TNF-\(\alpha\), but the drug combination has better effects. This study preliminarily proved the effects of the two drugs. However, the complex internal mechanism should be further studied in depth. The subsequent topics will discuss the signal pathway from multiple perspectives and levels. Meanwhile, researchers also hope that the finders can provide theoretical basis and practical significance for clinical treatment. This study preliminarily proved the efficacy of these two drugs, and TNF-\(\alpha\) may become a potential target for curing osteosarcoma and play a greater role in future research. The follow-up topic will explore the signal pathway from multiple perspectives and levels, and make further in-depth research on the complex internal mechanism. At the same time, I hope the research results can provide theoretical basis and practical significance for clinical treatment.

**Ethical Approval**

The study was approved by the Institutional Ethics Committee of General Hospital of Northern Theater Command, Shenyang, Liaoning, China.
Statement of Human and Animal Rights
This article does not contain any studies with human or animal subjects.

Statement of Informed Consent
There are no human subjects in this article and informed consent is not applicable.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD
Xin-Wei Liu https://orcid.org/0000-0002-9184-1707

References
1. Ritter J, Bielack SS. Osteosarcoma. Ann Oncol. 2010;21(7):320–325.
2. Hannah KB, Marta TG, Dominique H. Cancer stem cells in osteosarcoma. Cancer Lett. 2017;386:189–195.
3. Harrison DJ, Geller DS, Gill JD, Lewis VO, Gorlick R. Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther. 2018;18(1):67–77.
4. Dorothe C, Stefan SB. Current strategies of chemotherapy in osteosarcoma. Int Orthop. 2006;30(6):445–451.
5. Megan EA. Update on survival in osteosarcoma. Orthop Clin North Am. 2016;47(1):445–451.
6. Leo K, Gevorg T, Stefan B. Novel insights and therapeutic interventions for pediatric osteosarcoma. Future Oncol. 2017;13(4):357–368.
7. Elena T, Laura R, Francesca P. Multimodal transfer of MDR by exosomes in human osteosarcoma. Int J Oncol. 2016;49(1):189–196.
8. Eugene V, Domagoj V. Intracellular regulation of TNF activity in health and disease. Cytokine. 2018;101:26–32.
9. Horiuichi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford). 2010;49(7):1215–1228.
10. Sébastien P, Amit K, Georges H. Targeting TNF and TNF receptor pathway in HIV-1 infection: from immune activation to viral reservoirs. Viruses. 2017;9(4):64.
11. Arun D, Subramanya H, Jacqueline L. Transmembrane TNF-dependent Uptake of anti-TNF antibodies. Mabs. 2017;9(4):680–695.
12. Josephs SF, Ichim TE, Prince SM, Kesari S, Marincola FM, Escobedo AR, Jaffri A. Unleashing endogenous TNF-alpha as a cancer immunotherapeutic. J Transl Med. 2018;16(1):242.
13. Qian Q, Cao X, Wang B, Qu Y, Qian Q, Sun Z, Feng F. TNF-α-TNFR signal pathway inhibits autophagy and promotes apoptosis of alveolar macrophages in coal worker’s pneumoconiosis. J Cell Physiol. 2019;234(5):5953–5963.
14. Takanori S, Naoto I. The TNF-TNFR family of Co-signaling molecules. Adv Exp Med Biol. 2019;1189:53–84.
15. Muhammad SHA, Kanwal R, Aamira L. Tumor necrosis factor-alpha: role in development of insulin resistance and pathogenesis of type 2 diabetes mellitus. J Cell Biochem. 2018;119(1):105–110.
16. Zhang G, Zhang J, Kuang M, Lin P. The role of TNF alpha polymorphism and expression in susceptibility to nasal polyps. Immunol Invest. 2018;47(4):360–371.
17. Li H, Zhang X, Gao L, Min J, Zhang Y, Zhang R, Yang Y. TNF-alpha is upregulated in subacute thyroiditis and stimulates expression of miR-155-5p in thyroid follicle cells. Discov Med. 2018;26(142):67–77.
18. Lai WF, Lin MC. Chemotherapeutic Drugs Interference With Gene Delivery Mediated by Chitosan-Graft-Poly(ethyleneimine). PLoS One. 2015;10(5):e0126367.
19. Rancoule C, Guy JB, Vallard A, Ben Mrad M, Rehailia A, Magné N. Les 50 ans du cisplatine [50th anniversary of cisplatin]. Bull Cancer. 2017;104(2):167–176.
20. Sebastian IAA, Dudley WL. Rapamycin: an Inhibitor of aging emerges from the soil of Easter Island. J Gerontol A Biol Sci Med Sci. 2016;71(7):841–849.
21. Tanwar PS, Kaneko-Tarui T, Zhang L, Tanaka Y, Cram CP, Teixeira JM. Stromal liver kinase B1 [STK11] signaling loss induces oviductal adenomas and endometrial cancer by activating mammalian target of rapamycin complex 1. PLoS Genet. 2012;8(8):e1002906.
22. Sun HB, Wang HY, Wu B, Wang ZF, Wang LZ, Li FQ, Wu JD, Zhang LN. The inhibitory effects of cisplatin-radiation combination treatment on malignant osteosarcoma MG-63 cells and BRCA1-p53 pathways are more efficient than single treatments. Oncol Lett. 2019;18(6):6385–6396.
23. Friebele JC, Peck J, Pan X, Abdel-Rasoul M, Mayerson JL. Osteosarcoma: a Meta-analysis and review of the literature. Am J Orthop (Belle Mead NJ). 2015;44(12):547–553.
24. Biazzo A, Paolis MDe. Multidisciplinary approach to osteosarcoma. Acta Orthop Belg. 2016;824(4):690–698.
25. Prakash S, Alberto S.TNF-a (Tumor Necrosis Factor-a). Arterioscler Thromb Vasc Biol. 2018;38(11):2542–2543.
26. Torre-Amione G, Vooletich MT, Farmer JA. Role of tumour necrosis factor-α in the progression of heart failure. Drugs. 2000;59(4):745–751.
27. Yeremenko N, Zwerina K, Rigter G, Pots D, Fonseca JE, Zwerina J, Schett G, Baeten D. Tumor necrosis factor and interleukin-6 differentially regulate Dkk-1 in the inflamed arthritic joint. Arthritis Rheumatol. 2015;67(8):2071–2075.
28. Thomas PS. Tumor necrosis factor alpha: the Role of this multiple cytokine in asthma. Immunol Cell Biol. 2001;79(2):132–140.
29. Li W, Yu ZX, Ma BF. The increase of miR-27a affects the role of cisplatin on proliferation and migration capacities of liver cancer cells. Eur Rev Med Pharmacol Sci. 2018;22(17):5490–5498.

30. Liu J, Shen JX, Wu HT, Li XL, Wen XF, Du CW, Zhang GJ. Collagen 1A1 (COL1A1) promotes metastasis of breast cancer and is a potential therapeutic target. Discov Med. 2018;25(139):211–223.

31. Li M, Zhou Y, Chen C, Yang T, Zhou S, Chen S, Wu Y, Cui Y. Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis. Orphanet J Rare Dis. 2019;14(1):39.